IPP Bureau
Samsung Epis launches new biotech subsidiary Epis NexLab
By IPP Bureau - November 12, 2025
The new company aims to transform cutting-edge, highly scalable technologies into innovative drug discovery platforms
FDA grants Orphan Drug Designation for Tinostamustine in malignant glioma
By IPP Bureau - November 12, 2025
Tinostamustine is an investigational drug with a potential first-in-class mechanism combining bifunctional alkylating activity and pan histone deacetylase (HDAC) inhibition
Synchron raises $200 million to power non-surgical brain interface commercialization
By IPP Bureau - November 11, 2025
New funding to advance non-surgical brain interface technology and expand clinical and engineering capabilities globally
Mount Sinai to implement Microsoft Dragon Copilot for clinical documentation
By IPP Bureau - November 11, 2025
Dragon Copilot integrates generative AI, ambient listening, and natural language processing (NLP) to capture and document care directly
Trump clinches historic deal as Lilly, Novo slash U.S. weight-loss drug prices
By IPP Bureau - November 11, 2025
Agreements mark a major victory in the President’s long-term pledge to lower prescription drug costs for Americans
CereCore joins oracle partner network to strengthen healthcare IT and EHR services
By IPP Bureau - November 11, 2025
The partnership aligns with the launch of Oracle Health’s next-generation electronic health record
Teva’s AUSTEDO and AUSTEDO XR demonstrate real-world improvement in patients with tardive dyskinesia
By IPP Bureau - November 11, 2025
The results demonstrated meaningful reductions in the severity of involuntary movements and notable improvements in patient-reported quality of life
Nitinotes secures CE mark for automated suturing platform ‘EndoZip’
By IPP Bureau - November 11, 2025
Enabling a new era in minimally invasive obesity treatment across Europe
Granules Life Sciences receives first FDA approval for Hyderabad facility
By IPP Bureau - November 11, 2025
Gilead’s Trodelvy falls short on progression-free survival in key breast cancer trial
By IPP Bureau - November 10, 2025
While the trial fell short of demonstrating a statistically significant PFS benefit compared to chemotherapy, early data suggest a potential overall survival advantage
AstraZeneca delivers double-digit growth
By IPP Bureau - November 10, 2025
The pharma giant's 11% rise in total revenue to $43.2 billion highlights consistent execution of its growth strategy
SOUKYA launches Rs. 125 crore, 100-bed AYUSH hospital in Bengaluru
By IPP Bureau - November 10, 2025
The upcoming facility marks a strategic milestone in SOUKYA’s mission to make evidence-based holistic healthcare
Johnson & Johnson gets FDA nod for new depression treatment
By IPP Bureau - November 10, 2025
This approval is based on positive results from two Phase 3, global, double-blind, placebo-controlled trials
Zydus Lifesciences posts Q2 FY26 PAT at Rs. 1,258.6 Cr
By IPP Bureau - November 10, 2025
Organic capex during the quarter amounted to Rs. 491.1 crore, supporting ongoing business expansion initiatives
Touchlight unveils next-gen circular DNA portfolio for advanced gene therapies
By IPP Bureau - November 10, 2025
The expanded mbDNA portfolio delivers enhanced stability, reduced immunogenicity, and broad compatibility with gene insertion and expression technologies
